Apremilast Therapy for Acute Gouty Arthritis

Status Withdrawn

Clinical Trial Summary

The purpose of the study is to learn about a possible new medicine, apremilast, for treating acute gout and compare how it works to indomethacin, a medication that has been used to treat gout for over 50 years.

In order to learn about apremilast, half the participants in this study will receive apremilast and half the participants in this study will receive indomethacin.

This study will measure the severity and duration of acute gout attacks in research participants, as well as measures of quality of life and any side effects or adverse reactions to the medication.

There will be three study visits: a screening/baseline visit on Day 1, a visit to evaluate response to treatment with study medication at Day 7, and a follow-up visit at Day 21.

Clinical Trial Description

WITHDRAWN ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00997581
Study type	Interventional
Source	Dartmouth-Hitchcock Medical Center
Contact
Status	Withdrawn
Phase	Phase 2
Start date	April 2010
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02674776` - Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout	Phase 3
Not yet recruiting	`NCT05925166` - Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout	N/A
Completed	`NCT00798369` - Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients	Phase 2
Active, not recruiting	`NCT05328531` - Clinical Study of Genakumab for Injection in Patients With Acute Gout	Phase 1/Phase 2
Completed	`NCT01080131` - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.	Phase 3
Recruiting	`NCT05936268` - Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare	Phase 2
Not yet recruiting	`NCT05936281` - Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy	Phase 2
Recruiting	`NCT05588908` - A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout	Phase 1/Phase 2
Recruiting	`NCT05698680` - Prednisolone Versus Colchicine for Acute Gout in Primary Care	Phase 4
Recruiting	`NCT05983445` - Safety & Efficacy of Genakumab in Patients With Frequent Flares	Phase 3
Completed	`NCT00142558` - A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)	Phase 4
Not yet recruiting	`NCT06169891` - A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout	Phase 3
Completed	`NCT01029652` - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study	Phase 3